Infectious Diseases Research Collaboration, Kampala, Uganda.
Am J Trop Med Hyg. 2013 Apr;88(4):736-43. doi: 10.4269/ajtmh.12-0654. Epub 2013 Feb 4.
Artemisinin-based combination therapies (ACTs) and trimethoprim-sulfamethoxazole (TS) prophylaxis are important tools for malaria control, but there are concerns about their effect on gametocytes, the stage of the parasite responsible for transmission. We conducted a longitudinal clinical trial in a cohort of HIV-infected and uninfected children living in an area of high malaria transmission intensity in Uganda. Study participants were randomized to artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) for all treatments of uncomplicated malaria (N = 4,380) as well as TS prophylaxis for different durations. The risks of gametocytemia detected by microscopy in the 28 days after antimalarial therapy were compared using multivariate analyses. The risk of gametocyte detection was significantly higher in patients treated with DP compared with AL (adjusted relative risk = 1.85, P < 0.001) and among children prescribed TS prophylaxis (adjusted relative risk = 1.76, P < 0.001). The risk of gametocytemia and its potential for increasing transmission should be considered when evaluating different ACTs and TS prophylaxis for malaria control.
青蒿素为基础的联合疗法(ACTs)和磺胺多辛-乙胺嘧啶(TS)预防是疟疾控制的重要工具,但人们担心它们对配子体(寄生虫负责传播的阶段)的影响。我们在乌干达疟疾传播强度较高的地区对一组 HIV 感染和未感染的儿童进行了一项纵向临床试验。研究参与者被随机分配接受青蒿琥酯-咯萘啶(AL)或双氢青蒿素-哌喹(DP)治疗所有未合并疟疾(N = 4,380),并接受不同时间的 TS 预防。使用多变量分析比较了抗疟治疗后 28 天内镜检发现配子体血症的风险。与 AL 相比,DP 治疗的患者(校正相对风险 = 1.85,P < 0.001)和接受 TS 预防的儿童(校正相对风险 = 1.76,P < 0.001)中检测到配子体的风险显著更高。在评估疟疾控制的不同 ACTs 和 TS 预防时,应考虑配子体血症的风险及其增加传播的潜在风险。